cc: Life Science Podcast

Kris Barnette is a creative powerhouse—the President of All Good Marketing and an adjunct professor at Kent State—who brings a level of “swagger” to life science branding. Kris is focused on turning Ontario, Canada, into a global commercial powerhouse in the life sciences. Ontario has everything a biotech hub needs: world-class infrastructure, elite academic institutions, and incredible talent. Ho...

At the Advanced Lateral Flow Conference, I spoke with Jeremy Elser, Head of Science Operations at Palantir and founder of Ship of Theseus , a biotech company tackling longevity and regenerative medicine. The name refers to the Greek thought experiment about replacing every plank on a ship over time, similar to Jeremy’s vision to keep rebuilding the human body, replacing the cellular “planks” so it...

This episode is a double from my visit to the Advanced Lateral Flow Conference . Usability is Innovation: Atomo Diagnostics Atomo Diagnostics set out more than a decade ago to solve a surprisingly human problem in diagnostics: complexity. Founder John Kelly describes how even the best rapid tests—validated in pristine lab environments—often fail when they reach the real world, where people have no...

The Future of Science Marketing: AI, Upskilling, and Human Connection I recently had a conversation with Isabel Verniers, partner at the Marketing Technology and Innovation Institute (MTI2) in Belgium, about how life science companies are adapting to rapid technological change while maintaining their scientific rigor. One of the interesting threads we explored was the tension between scientific an...

Carter Mitchell , Chief Scientific Officer at Kemp Proteins , brings scientific rigor and an artist’s imagination to the world of protein design and production. In this episode, recorded at the Advanced Lateral Flow Conference , we explore how his company is pushing the boundaries of protein expression, quality, and analysis using tools that merge machine learning, automation, and human creativity...

When it comes to biotech innovation, data and logic should drive decision-making, but sometimes stories take the wheel. This week, I spoke to Julien Willard , a board advisor and strategist for biopharma leaders. He had written a post on LinkedIn about how biologics may be favored over small molecules when logic suggests otherwise. Despite perceptions, small molecules still make up 73% of all FDA...

Anis Fahandej-Sadi is building two businesses. He is the founder of TLDR Biotech , a daily newsletter that condenses life science news into a quick, skimmable format, and creator of Science 2 Sales , a service designed to help biotech companies accelerate business development. In this conversation, Anis opens up about his career journey, the lessons he’s learned in building content-driven business...

PCR has been a staple of molecular biology for over 30 years. But as Yann Jouvenot , Director of Product at N6 Tec , explains, no technology is ever too mature to be reinvented. In this walk and talk interview along the Martinez (CA) shoreline, we explore how N6 Tec’s ICON PCR technology is reshaping genomics workflows: reducing artifacts, unlocking discoveries at the margins, and giving postdocs...

Tino Chow’s career spans three worlds—military operations in Singapore, industrial design at Rhode Island School of Design, and entrepreneurship. That mix has shaped his work at Giant Shoulders, where he helps challenger brands in medtech, venture capital, and startups bring innovations to market. It takes more than a great product and strong marketing. Without a sustainable business model, impact...

Tiffany Payne recently attended the American Society of Mass Spectrometry meeting—just two weeks after being laid off—and received a badge with "NONE" printed in giant letters under “Company.” She could only laugh to keep from crying. It’s sometimes hard to separate our job from our identity. Tiffany turned it into a conversation starter: “I’m the CEO of None Industries—offering nothing to no one,...

When you're selling something truly new, you're not just fighting for market share – you're fighting to create a market that doesn't exist yet. A big part of that battle is figuring out your sales process. Chris Morrison from ViaVerus and Brian Jamieson from Diagnostic Biochips shared their experience on this week’s episode. Chris Morrison introduced the "innovation death spiral." It goes like thi...

When Joachim Eeckhout says he started small, he’s not kidding. He and a friend began curating biotech news from a Paris dorm room, eventually launching LaBiotech.eu , a media brand that became a trusted voice in European biotech. What caught my attention is how they learned the landscape: by biking across France with a camera, interviewing CEOs, and turning it into a documentary. That’s how they b...

Jin Kim is the founder and CEO of Miracle, a company helping biotech teams accelerate clinical trials by automating operational insights. Trials are a data problem and Miracle solves it by unifying siloed systems into one real-time dashboard. That has helped some clients finish trials 3–4 months ahead of schedule. Many trial operations still rely heavily on Excel. It’s easy, familiar, and free. Bu...

Nick Clare is a co-founder of Succession Bio and co-host of the SalesDNA podcast. I recently spoke to Harrison Wade, the other co-founder here. Nick's journey into sales wasn't a planned career move. It was the result of "fear and desperation," as he put it. Nick was working as a scientist in the lab when his wife was 14 weeks pregnant with their third child. 20 days before Christmas, he was made...

I had a fantastic conversation with Abdul Rastagar , founder of Serona Marketing , about his mission to cut the b******t out of marketing. Abdul runs both a podcast and newsletter with that exact title. It’s pretty clear he feels strongly about this. I thought it would be fun to find out what’s been bugging him lately. I was not disappointed. Abdul's beef is that we're stuck using outdated marketi...

When we talk about gene expression, most of the focus is on DNA and RNA sequences, but there’s a lesser-known, more subtle layer of regulation: RNA modifications. In this episode, I spoke with Gudrun Stengel , CEO and co-founder of Alida Biosciences, to explore how this fine-tuning mechanism affects everything from cell differentiation to cancer survival, and how her company is helping to decode i...

I had a great time speaking with Meg Schlabs , co-founder and creative director at Wizardly. While it may be difficult for early-stage life science companies to think about branding, Meg makes a clear case for why it matters, even before you go to market, especially when you are trying to raise capital and recruit talent. Meg’s LinkedIn profile mentions that she likes books and cheesy videos. So b...

This webinar is also available for listening: In this live conversation, I sat down with two of my friends, both smart thinkers in life science, Elizabeth Chabe (CEO of High Touch Group) and Hamid Ghanadan (Founder of the Linus Group) to talk about disruptions in science from funding cuts and possibly tariffs. The goal of this session was to make sense of what’s happening and offer perspective on...

Every day, roughly 10 people in the U.S. die from SUDEP (Sudden Unexpected Death in Epilepsy), most found face down in bed. Soterya is changing that with an ML-powered bed that detects sleep position and can gently reposition a person without waking them. I spoke with Norman Wen about how ML, robotics, and thoughtful design are merging to improve sleep health, and potentially save lives. Norman is...

Recently, I’ve enjoyed interviewing people I have never spoken to before. Harrison Waid, the co-founder of Succession , is one of those. Shout out to Teddy Lin for connecting us. I took this as an opportunity to learn about Harrison and his business as well as a personal challenge to interview someone “cold”. OK, I did some research, so maybe “room temperature”. First of course, I needed him to ex...

Large language models (LLMs) seem to dominate the discussions, at least in my world lately. In this episode and the next, we’re diving into AI on a different scale. In this episode, I spoke with Josh Hinckley , co-founder and CEO of Bioqore . AI is being applied to the way we make things — in this case, food. Josh’s background in materials chemistry has led him to focus on process optimization for...

When I invited Max Gilbert on the podcast, I suspected the conversation might go beyond sales tactics. Max is the founder of Tiferet Consulting, but he’s also a sourdough baker, amateur rabbi, armchair philosopher, and like me, a pretty bad golfer. Our conversation covered everything from startup struggles to spiritual identity and the joys of sourdough. Helping Scientists Become Salespeople Max w...

I had the chance to speak with Petrina Kamiya, Global Head of AI Platforms and VP at Insilico Medicine, as well as President of Insilico Medicine Canada. Insilico Medicine is what Petrina calls a “tech bio”—developing both AI platforms and therapeutic assets, with a flexible model licensing both. Their pharma.ai platform was created to address challenges in drug discovery all the way from target i...

I’ve never been great at conflict. Like a lot of people, I’ve leaned toward avoiding it—especially in the workplace. But I know that’s not a useful strategy in the long run, which is why I was excited to talk with Deb Nathan , a conflict navigation coach, on Life Science Marketing Radio. Right off the bat, Deb drew a distinction between conflict resolution and conflict navigation . Resolution impl...

In this episode of Life Science Marketing Radio, I spoke with Oliver Pearce, VP and Head of Marketing at Epista Life Sciences. Oliver brings a unique perspective to life science marketing, having started his career in the nightlife and hospitality industry. Now leading marketing at Epista, a consultancy firm specializing in pharmaceutical quality, regulatory compliance, and commercialization, we t...